eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Provided By GlobeNewswire

Last update: May 9, 2024

Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024

Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025